So­bi rene­go­ti­ates nir­se­vimab deals, to pay $81M for US roy­al­ties and axe As­traZeneca agree­ment

So­bi has an­nounced two new up­dates that it said would “stream­line” pre­vi­ous arrange­ments re­lat­ed to nir­se­vimab and give the com­pa­ny more flex­i­bil­i­ty.

So­bi said Sun­day that it reached a new roy­al­ty agree­ment with Sanofi on net US sales of the RSV an­ti­body, cur­rent­ly brand­ed as Bey­for­tus in the re­gions where it is ap­proved. Ac­cord­ing to a com­pa­ny state­ment, So­bi will start out with a 25% roy­al­ty of all US sales, start­ing at launch and paid out every quar­ter. As part of the agree­ment, So­bi is pony­ing up $66 mil­lion to re­im­burse Sanofi for pre­vi­ous R&D ex­pens­es.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER